



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/517,338
Applicant : WARNAAR et al.
Filed : December 9, 2004
TC/A.U. : 1642
Examiner : Catherine Joyce
Confirmation No. : 2944

Docket No. : 2923-672
Customer No. : 06449

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith Form PTO-1449 listing publications that the Office may wish to consider in examination of the subject application.

Pursuant to 37 C.F.R. § 1.17(p), please charge the required fee to Deposit Account No. 02-2135. An additional copy of this document is enclosed.

Respectfully submitted,

By: Donald V. Scaltrito

Donald V. Scaltrito
Patent Agent for Applicants
Registration No. 59,985
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040

04/09/2007 SSANDARA 00000014 022135 10517338
01 FC:1806 180.00 DA



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/517,338
Applicant : WARNAAR et al.
Filed : December 9, 2004
TC/A.U. : 1642
Examiner : Catherine Joyce
Confirmation No. : 2944

Docket No. : 2923-672
Customer No. : 06449

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant submits herewith Form PTO-1449 listing publications that the Office may wish to consider in examination of the subject application.

Pursuant to 37 C.F.R. § 1.17(p), please charge the required fee to Deposit Account No. 02-2135. An additional copy of this document is enclosed.

Respectfully submitted,

By: Donald V. Scaltrito
Donald V. Scaltrito
Patent Agent for Applicants
Registration No. 59,985
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202) 783-6040



FEE TRANSMITTAL
for FY 2007
(Large Entity)

User Not Listed

		Complete if Known	
		Application Number	10/517,338
		Filing Date	December 9, 2004
		First Named Inventor	WARNAAR et al.
		Examiner Name	Catherine Joyce
		Group Art Unit	1642
<input type="checkbox"/> Application claims small entity		Attorney Docket Number	2923-672
Total Amount of Payment	\$180.00	Confirmation Number	2944

METHOD OF PAYMENT (check one)

1. ☒ The Commissioner is hereby authorized to charge additional fees and credit any overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Manbeck
- ☒ Charge any Additional Fee Required Under 37 CFR 1.16 and 1.17 to Deposit Account No. 02-2135.
2. ☐ Payment Enclosed

FEE CALCULATION

1. FILING, SEARCH AND EXAMINATION FEES

Code	Fee	Fee Description	Fee Paid
1001	300	Utility Filing Fee	[]
1111	500	Utility Search Fee	[]
1311	200	Utility Examination Fee	[]
1002	200	Design Filing Fee	[]
1112	100	Design Search Fee	[]
1312	130	Design Examination Fee	[]
1003	200	Plant Filing Fee	[]
1113	300	Plant Search Fee	[]
1313	160	Plant Examination Fee	[]
1004	300	Reissue Filing Fee	[]
1114	500	Reissue Search Fee	[]
1314	600	Reissue Examination Fee	[]
1005	200	Provisional Filing Fee	[]

SUBTOTAL \$

2. CLAIMS

	Extra Claims	Fee	Fee Paid
Total Claims [] - 20* = [] x \$ 50 = []			
Independent Claims [] - 3* = [] x 200 = []			
Multiple Dependent Claims + 360 = []			

*or number previously paid, if greater;

SUBTOTAL \$

3. APPLICATION SIZE FEE

Total Sheets: [] - 100 = []/50 = []** x \$250 = []

**Number of each additional 50 or fraction thereof

SUBTOTAL \$

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Code	Fee	Fee Description	Fee Paid
1051	130	Surcharge - late filing fee or oath	[]
1052	50	Surcharge - late provisional filing fee or cover sheet	[]
1053	130	Non-English specification	[]
1812	2,520	For filing a request for reexamination	[]
1804	920	Requesting publication of SIR prior to Examiner action	[]
1805	1,840	Requesting publication of SIR after Examiner action	[]
1251	120	Extension for reply within first month	[]
1252	450	Extension for reply within second month	[]
1253	1,020	Extension for reply within third month	[]
1254	1,590	Extension for reply within fourth month	[]
1255	2,160	Extension for reply within fifth month	[]
1401	500	Notice of Appeal	[]
1402	500	Filing a brief in support of an appeal	[]
1403	1,000	Request for Oral Hearing	[]
1451	1,510	Petition to institute a public use proceeding	[]
1452	500	Petition to revive - unavoidable	[]
1453	1,500	Petition to revive - unintentional	[]
1807	50	Processing fee under 37 CFR 1.17(q)	[]
1806	180	Submission of Information Disclosure Statement	[180]
1809	790	Filing a submission after final rejection (37 CFR 1.29(a))	[]
1810	790	For each additional invention to be examined (37 CFR 1.129(b))	[]
1801	790	Request for Continued Examination (RCE)	[]
1802	900	Request for expedited examination of a design application	[]
1504	300	Publication fee for early, voluntary, or normal publication	[]
1505	300	Publication fee for republication	[]
1455	200	Filing application for patent term adjustment	[]
1456	400	Request for reinstatement of term reduced	[]
1814	130	Statutory Disclaimer	[]
8021	40	Recording each patent assignment per property (times number of properties)	[]
Other fee (specify)			[]

SUBTOTAL \$180

SUBMITTED BY		Complete (if applicable)	
NAME AND REG. NUMBER	Donald V. Scaltrito, Reg. No. 59,985		
SIGNATURE	Donald V. Scaltrito	DATE	April 3, 2007
		DEPOSIT ACCOUNT USER ID	02-2135



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/517,338
				Filing Date	December 9, 2004
				First Named Inventor	WARNAAR et al.
				Group Art Unit	1642
				Examiner Name	Catherine Joyce
				Confirmation No.	2944
Sheet	1	of	3	Attorney Docket Number	2923-672

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	5,104,652		Houghton et al.	04-14-1992
	2	5,772,997		Hudziak et al.	06-30-1998
	3	5,830,452		Bauer et al.	11-03-1998

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/517,338
				Filing Date	December 9, 2004
				First Named Inventor	WARNAAR et al.
				Group Art Unit	1642
				Examiner Name	Catherine Joyce
				Confirmation No.	2944
Sheet	2	of	3	Attorney Docket Number	2923-672

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
	4	WO	93/18152	A1	CIBA Corning Diagnostics Corp.	09-16-1993	
	5	WO	97/41831	A1	Cornell Research Foundation, Inc.	11-13-1997	
Examiner Signature					Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/517,338
				Filing Date	December 9, 2004
				First Named Inventor	WARNAAR et al.
				Group Art Unit	1642
				Examiner Name	Catherine Joyce
				Confirmation No.	2944
Sheet	3	of	3	Attorney Docket Number	2923-672

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²	
	6	Christianne BUSKENS et al., "Adenocarcinomas of the Gastro-esophageal junction: a comparative study of the gastric cardia and the esophagus with respect to cyclooxygenase-2 expression", Digestive Disease Week Abstracts and Itinerary Planner, Vol. 2003, 2003, page Abstract No. 850	AB	
	7	Kim A. MARGOLIN, "Interleukin-2 in the Treatment of Renal Cancer", Seminars in Oncology, Vol. 27, No. 2, April 2002, pages 194-203		
	8	Peter F.A. MULDER et al., "The Role of Adjuvant Immunotherapy in Renal Cell Carcinoma", Current Urology Reports, 2002, Vol. 3 pages 44-49		
	9	Kendall A. SMITH, "Lowest Dose Interleukin-2 Immunotherapy", Blood, Vol. 81, No. 6, March 15, 1993, pages 1414-1423		
	10	Paul M. SONDEL et al., "Clinical and Immunological Effects of Recombinant Interleukin 2 Given by Repetitive Weekly Cycles to Patients with Cancer", Cancer Research 48, May 1, 1988, pages 2561-2567		
	11	Jeff A. SOSMAN et al., "Repetitive Weekly Cycles of Interleukin-2. II. Clinical and Immunologic Effects of Dose, Schedule, and Addition of Indomethacin", Journal of the National Cancer Institute Vol. 80, No. 18, November 16, 1988, pages 1451-1461		
	12	R. C. STEIN et al., "The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin 2", Br. J. Cancer 63, 1991, pages 275-278		
	13	J. R. TURNER et al., "MN antigen expression in normal, preneoplastic, and neoplastic esophagus: a clinicopathological study of a new cancer-associated biomarker", Hum Pathol 1997, Jun; 28(6):740-4, PubMed Abstract	AB	
	14	M.L. NASI et al., "Treatment (tx) with daily low-dose subcutaneous (sc) interleukin-2 (IL-2) followed by monoclonal antibody R24 against GD3 ganglioside in patients (pts) with metastatic melanoma (MM)", http://www.asco.org/prof/me/html/abstracts/ms/m_1770.htm , 1997	AB	
	15	Joost L. M. VISSERS et al., "The Renal Cell Carcinoma-associated Antigen G250 Encodes a Human Leukocyte Antigen (HLA)-A2.1-restricted Epitope Recognized by Cytotoxic T Lymphocytes", Cancer Research 59, November 1, 1999, pages 5554-5559		
Examiner Signature				Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.